IP Patents / Trademarks

Intellectual property is an important part of Paradigm’s strategic development and ownership of its repurposing programmes. Paradigm employs a multi-pronged approach, garnering protection from: exclusive supply agreements and partnerships; patents; and trademarks. We work closely with FB Rice in the development, registration and prosecution of our patents in order to secure a strong IP position.  Paradigm has registered trademarks for the BME product, ZILOSUL® and respiratory product RHINOSUL® for Allergic Rhinitis.

Patents & Patent Applications

Paradigm continues to pursue 3 main patent families in the areas of: bone marrow edema (BME); respiratory disease, including allergic rhinitis, asthma and chronic obstructive pulmonary disease (COPD); and alphaviral arthritis. More recently Paradigm has also acquired a patent application in the heart failure family.
Paradigm’s patent coverage includes:


In January 2018, Paradigm announced that it had been granted a European patent for the treatment of Bone Marrow Edema Lesions with Pentosan Polysulfate Sodium (PPS), and throughout 2018 has validated the patent in European member states. The European registration enhances Paradigm’s already strong patent position, adding to previously granted registrations in Australia, the United States, Japan, China, Canada, Taiwan, Singapore and other countries across the Asia-Pacific.


In September 2016, Paradigm announced a collaborative partnership with the Institute for Glycomics at Griffith University, whereby Paradigm was granted exclusive world-wide rights to commercialise a patent covering the use of PPS to treat alphavirus arthritis and joint pain.

Respiratory Disease

Paradigm has acquired patents over the use of PPS as a new treatment for respiratory diseases including Allergic Rhinitis (AR), Allergic Asthma (AA) and Chronic Obstructive Pulmonary Disease (COPS). Paradigm has registered patents in major markets including Australia, Canada, Europe, New Zealand, and The People’s Republic of China.
Further information on Paradigm’s Patent and IP position can be found in our ASX announcements and Annual Reports.


Paradigm has Trademarked its proprietary formulations of Pentosan Polysulphate Sodium for treatment of bone marrow edema (Zilosul®) and Allergic Rhinitis (Rhinosul®).

ZILOSUL Trade mark portfolio March 2016

CountryRegistration #Trade MarkDescription CombinedStatus
AUSTRALIA1639602ZILOSUL5 - Pharmaceutical preparationsREGISTERED
HONG KONG303294180ZILOSUL5 - Pharmaceutical preparationsREGISTERED
WIPO1238470ZILOSUL5 - Pharmaceutical preparationsREGISTERED
CHINA1238470ZILOSUL5 - Pharmaceutical preparationsREGISTERED
EUROPEAN UNION (CTM)1238470ZILOSUL5 - Pharmaceutical preparationsREGISTERED
JAPAN1238470ZILOSUL5 - Pharmaceutical preparationsREGISTERED
NEW ZEALAND1015728ZILOSUL5 - Pharmaceutical preparationsREGISTERED
PHILIPPINES1238470ZILOSUL5 - Pharmaceutical preparationsREGISTERED
SINGAPORE1238470ZILOSUL5 - Pharmaceutical preparationsREGISTERED
TAIWAN1722127ZILOSUL5 - Pharmaceutical preparationsREGISTERED
CANADAZILOSUL5 - Pharmaceutical preparationsPENDING
INDIAZILOSUL5 - Pharmaceutical preparationsPENDING
UNITED STATESZILOSUL005 - Pharmaceutical preparations for the treatment of orthopedic conditionsPUBLISHED
VIETNAMZILOSUL5 - Pharmaceutical preparationsPENDING
INDONESIAZILOSUL5 - Pharmaceutical preparationsPENDING

# All Trademarks owned by Paradigm Biopharmaceuticals Ltd